Stellar Biotechnologies, Inc. ( SBOT ) is a leading player in the sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH") and on November 3 it announced its uplisting to the NASDAQ. This is a significant milestone for Stellar and an important step in our corporate growth," said Frank Oakes, President, Chief Executive Officer and Chairman. "We anticipate that the listing of our shares on NASDAQ will raise our visibility within the investment community and with institutional investors, and will offer our shareholders an opportunity for increased liquidity." Since uplisting SBOT has duly seen an increase in both visibility and liquidity. The company is now trading near $9 a share having risen to as much as $12.87 in the last 12 months. It's obvious that investors can reap very good upside from companies that are newly uplisted. Companies like IEG Holdings Corp.